Cytel (United States)

Clinical efficacy/effectiveness, safety, and health-related quality of life associated with relapsed/refractory pediatric low-grade glioma treatments: systematic literature review

Abstract Background Patients with relapsed/refractory pediatric low-grade glioma (R/R pLGG) face considerable long-term morbidity. Most cases are driven by mitogen-activated protein kinase (MAPK) pathway alterations, for which several targeted agents have been evaluated. Systemat...

Incidence of New Malignancies in Severe Asthma: Comparison of Real-World Patients Treated with Benralizumab, Other Biologics, or Non-biologics

Clinical trials report no increased malignancy risk with benralizumab in severe asthma; however, trial populations are highly selective. To better define real-world safety, malignancy risk was compared among patients treated with benralizumab, other (non-benralizumab) biologics,...